Sociedad Americana de Hirudoterapia

Role of argatroban infusion in controlling clot formation in post-cardiac surgical extracorporeal membrane oxygenation in pediatrics: A case series of three patients

Research article published in Perfusion (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosFarmacología salivalSamhan LM et al. · Perfusion, 2026

Abstract

Anticoagulation in pediatric patients on extracorporeal membrane oxygenation (ECMO) presents significant challenges. Direct thrombin inhibitors (DTIs), such as argatroban, are increasingly considered when heparin is ineffective or contraindicated. However, guidelines regarding optimal dosing and monitoring remain established. This case series examines three pediatric patients who received argatroban infusion following cardiac surgery. We focus on titration challenges, complications, and outcomes. Patient 1, a 3-month-old girl, required a gradual increase in argatroban to 0.7 mcg/kg/min over 8 days. Patient 2, a 3-year-old boy, transitioned to argatroban due to suspected heparin-induced thrombocytopenia (HIT) and required doses up to 1.43 mcg/kg/min. Patient 3, a 23-month-old boy, reached 2.13 mcg/kg/min over 39 days. While patients were successfully decannulated, complications included arterial thrombosis, circuit thrombosis, and mild intracranial hemorrhage. In our series, effective argatroban doses ranged widely (0.18 to 2.13 mcg/kg/min), highlighting the need for individualized dosing, while optimal monitoring strategies remain to be established; lower doses are recommended for patients with hepatic impairment.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Anticoagulation in pediatric patients on extracorporeal membrane oxygenation (ECMO) presents significant challenges.

Por qué esto importa para la hirudoterapia

This case series examines the titration challenges, complications, and clinical outcomes of argatroban infusion for anticoagulation management in three pediatric patients on extracorporeal membrane oxygenation following cardiac surgery, highlighting the wide range of effective doses and the need for individualized dosing. The abstract identifies argatroban as a direct thrombin inhibitor but makes no mention of leeches, hirudin, hirudotherapy, or the leech secretome. As a small case series focused on a pharmaceutical anticoagulant in pediatric ECMO, its relevance to the American Society of Hirudotherapy is negligible, with no connection to leech-based therapies.

Citación

Role of argatroban infusion in controlling clot formation in post-cardiac surgical extracorporeal membrane oxygenation in pediatrics: A case series of three patients

Samhan LM et al. · Perfusion, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.